{"schema_version":"secwatch.filing_event.v1","accession":"0001610618-24-000074","form_type":"8-K","ticker":null,"cik":"0001610618","company_name":"Cidara Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.246445+00:00","generated_at":"2026-06-01T23:09:28.298952+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cidara reacquires CD388 flu program, raises $240M; Q1 revenue $8.5M, net loss $10.3M","bullets":["Reacquired exclusive global development and commercial rights to CD388 from Janssen; plans to initiate Phase 2b trial in upcoming Northern Hemisphere flu season.","Closed $240.0M private placement led by RA Capital; $85.0M used for upfront Janssen payment, remaining $155.0M funds runway through Phase 2b topline.","Divested rezafungin to Mundipharma; expects ~$128.0M cost savings over rezafungin patent life.","Q1 2024 revenue $8.5M (down from $26.1M YoY); net loss $10.3M vs net income $3.0M in prior year period.","Appointed three new board members (Tadvalkar, Spencer, Merson); executed 1-for-20 reverse stock split, shares trade under CDTX."],"urls":{"canonical":"https://secwatch.observer/filing/0001610618-24-000074","json":"https://secwatch.observer/filing/0001610618-24-000074.json","markdown":"https://secwatch.observer/filing/0001610618-24-000074.md","text":"https://secwatch.observer/filing/0001610618-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000074/0001610618-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000074/cdtx-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:09:28.298952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b080b7fad730322e6504cd7ff8ea28f3a03e9e90","claim":"Cidara Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $8.5 million.","evidence_excerpt":"Company’s multispecific CD73/PD-1 DFC, its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73. First Quarter 2024 Financial Results • Revenue totaled $8.5 million for the three months ended March 31, 2024, compared to $26.1 million for the same period in 2023. Revenue for the three months ended March 31, 2024 related to the achievement of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000074/0001610618-24-000074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}